
Caveats and Considerations
Source:vignettes/articles/Caveats-and-Considerations.Rmd
Caveats-and-Considerations.RmdThe applicability of pregnancy-identification algorithms depends on the available variables and the structure of your database.
These algorithms are designed for different scopes and are not universal. Always evaluate whether the algorithm aligns with your specific research question and consider any necessary tailoring. For instance, if your study focuses on pregnancies in older individuals, you may need to remove age-based exclusion criteria present in some algorithms (e.g., UMC or EMA).
If possible, after retrieving pregnancy-related reports, review individual cases to confirm correct flagging and check for unusual patterns.
Performance Limitations
- Not all relevant reports may be captured, and some may be incorrectly flagged.
- Performance varies across:
- Databases (due to structure and processing choices)
- Subpopulations (e.g., age groups)
- Regions (different reporting formats or recommendations)
- Reporter types (variation in reporting practices)
- Medication classes (e.g., vaccines vs. drugs)
Any deviation from the original algorithm affects performance. If possible, assess whether reports flagged differently by tailored vs. original algorithms are appropriate for your analysis.
Misclassification of pregnancy-related variables can
hinder proper adjustment for biases associated with pregnancy. For
further discussion, see: Fusaroli, M., Sartori, D., van Puijenbroek,
E.P. et al. (2025). Charting and Sidestepping the Pitfalls
of Disproportionality Analysis. Drug Safety.
DOI: 10.1007/s40264-025-01604-y
Complexity of Linked Information
Algorithms typically retrieve two populations:
mothers and prenatally exposed
individuals. Often, information about both is
co-present in the same report, making separation
challenging. For further discussion, see: Sandberg, L., Vidlin, S.H.,
K-Pápai, L. et al. (2025). Uncovering Pregnancy Exposures
in Pharmacovigilance Case Report Databases: A Comprehensive Evaluation
of the VigiBase Pregnancy Algorithm. Drug Safety, 48,
1103–1118.
DOI: 10.1007/s40264-025-01559-0
Contact
If you would like to give us feedback on the
package, share your work to motivate further
development of the package, or consult us on analyses
using these algorithms, please contact us via UMC:
https://who-umc.org/contact-information/help-and-support/